Trial Profile
An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Aug 2019
Price :
$35
*
At a glance
- Drugs Tenofovir exalidex (Primary)
- Indications Hepatitis B
- Focus Pharmacokinetics
- Sponsors ContraVir Pharmaceuticals; Hepion Pharmaceuticals
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
- 06 Feb 2018 According to a ContraVir Pharmaceuticals media release, company plans to present additional results at future scientific meetings.
- 06 Feb 2018 Status changed from recruiting to completed, according to a ContraVir Pharmaceuticals media release.